Live Feeds
● LIVE Updated 5h ago · 8 sources tracked

Psychedelics Stock, Up 190% This Year, Flies High Again

Definium Therapeutics announced positive topline results from the Phase 3 Panorama study of its LSD-based anxiety and depression drug, DT120 ODT. The therapy eased anxiety in a large trial, marking another successful outcome for the treatment. This latest trial win pushes the company closer toward a Food and Drug Administration submission for the anxiety drug. Following the positive trial news, the psychedelics stock surged again, adding to a substantial gain recorded over the course of the year. Investors and market watchers are closely tracking the regulatory progress of the treatment as clinical testing advances.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Definium Therapeutics announced positive topline results from the Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder.
  • ✓ The LSD-based drug scored another trial win for anxiety and depression.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Definium Therapeutics secured another Phase 3 trial win for its LSD-based anxiety and depression drug, DT120 ODT.

Live updates

  1. Definium LSD Drug Scores Another Trial Win

    Definium Therapeutics announced positive topline results from the Phase 3 Panorama study of its LSD-based anxiety and depression drug, DT120 ODT. The therapy eased anxiety in a large trial, marking another successful outcome for the treatment. This latest trial win pushes the company closer toward a Food and Drug Administration submission for the anxiety drug. Following the positive trial news, the psychedelics stock surged again, adding to a substantial gain recorded over the course of the year. Investors and market watchers are closely tracking the regulatory progress of the treatment as clinical testing advances.

    Why it matters

    The company is advancing its pharmaceutical pipeline targeting mental health conditions using psychedelic compounds. DT120 ODT is designed to treat generalized anxiety disorder through LSD-based therapy. Success in multiple late-stage trials strengthens the clinical validation for psychedelic-based medicines seeking regulatory approval. The stock market has responded strongly to these developments, reflecting heightened commercial interest in novel psychiatric treatments.

    What is confirmed

    • Definium Therapeutics announced positive topline results from the Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder.
    • The LSD-based drug scored another trial win for anxiety and depression.

    Still unconfirmed

    • The psychedelics stock is up 190% this year.

    What to watch next

    • Definium submission to the FDA for the LSD anxiety drug
    • Further regulatory updates on the DT120 ODT program
    Sources used for this update (7)
    1. Investor's Business Daily — Psychedelics Stock, Up 190% This Year, Flies High Again
    2. Reuters — Definium's LSD-based anxiety, depression drug scores another trial win
    3. fiercebiotech.com — Definium LSD drug goes 3 for 3 with another pivotal anxiety trial win
    4. Yahoo Finance — Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
    5. statnews.com — Definium’s LSD therapy eased anxiety in second large trial
    6. FirstWord Pharma — Definium's psychedelic notches another Phase III win in anxiety
    7. BioSpace — Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community